Stocks to Watch 01-27-12

UNDT, OXGN, MITI, ENMD, NEGS, IRSN

Our Stocks to Watch tomorrow include Universal Detection Technology (OTCBB: UNDT), OXiGENE Inc. (NASDAQ: OXGN), Micromet Inc. (NASDAQ: MITI), EntreMed Inc. (NASDAQ: ENMD), NX Global Inc. (OTCBB: NEGS) and ISC8 Inc. (OTCBB: IRSN).

UNIVERSAL DETECTION TECHNOLOGY (OTCBB: UNDT)
"Up 100.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/UNDT.php

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.

UNDT News:

December 15 - Universal Detection Technology Announces Sale of Biological Weapon Detection Devices to US Army

Handheld Assays Detect the Presence of Biological Hazards Including Anthrax and Ricin

Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies that protect against biological, chemical, and radiological threats, announced today that that it has received a purchase order from the US Army for its biological detection equipment.

A report released by the WMD Center released in October found that the United States is unprepared for a large-scale biological attack, despite spending more than $65 billion on biodefense over the past decade. The report warned that the threat of biological weapons is now greater than ever as a result of technological advances: "A small team of individuals with training in key disciplines can produce the type of bioweapons created by nation-states in the 1960s."

"We are very pleased to supply our armed forces with the tools to detect agents of Bioterror such as Anthrax and Ricin," said Mr. Jacques Tizabi, UNDT's Chairman and CEO. "We understand that, unfortunately, the threat posed by Biological weapons is very dangerous to the government and the civilian sectors," he added.

OXIGENE INCORPORATED (NASDAQ: OXGN)
"Up 24.53% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/OXGN.php

OXiGENE, Inc. develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase Ib and II clinical trials for other solid tumors, including non-small cell lung cancer, platinum resistant ovarian cancer, and head-and-neck cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, an ortho-quinone prodrug, which is in Phase I clinical trial for solid tumors. The company was founded in 1988 and is headquartered in Waltham, Massachusetts.

OXGN News:

December 12 - OXiGENE and Azanta A/S Establish Partnership to Provide ZYBRESTAT™ for ATC in Europe on Named Patient, Compassionate Use Basis

OXiGENE, Inc. (NASDAQ: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, and Azanta Danmark A/S, a specialty pharmaceutical company focused on oncology, women's health and addiction medicine, have established a partnership agreement to provide access to ZYBRESTAT for the treatment of patients in Europe and Canada with anaplastic thyroid cancer (ATC) on a compassionate use basis. OXiGENE's newly-formed Named Patient Program (NPP), to be managed by Azanta, provides a regulatory mechanism to allow healthcare professionals in Europe and Canada to prescribe ZYBRESTAT to individual ATC patients while it is still in development.

Under the terms of the agreement, OXiGENE will provide ZYBRESTAT to Azanta. Azanta will serve as exclusive distributor for ZYBRESTAT in the specified territory for this purpose and will provide ZYBRESTAT to physicians solely to treat ATC on a compassionate use basis in the territory covered by the agreement until such time as ZYBRESTAT may obtain marketing approval in that territory. The territory includes the European Union, including the Nordic countries and Switzerland, and Canada, and the agreement may also be expanded to include other countries on a country-by-country basis. OXiGENE and Azanta will cooperate on regulatory activities relating to ZYBRESTAT for the treatment of ATC within the territory. There will be no transfer of ownership of intellectual property rights for ZYBRESTAT to Azanta under the terms of the agreement.

Commented Peter J. Langecker, M.D., Ph.D., Chief Executive Officer of OXiGENE: "This agreement represents a critical milestone in the ongoing development of ZYBRESTAT, reflecting OXiGENE's commitment to facilitate access to this potentially valuable therapy by ATC patients who have no other treatment options. We are delighted to work in partnership with Azanta, a privately held European specialty pharmaceutical company with specialized technical and regulatory expertise in implementing compassionate use programs. While Azanta focuses on our Named Patient Program, we will continue to pursue a global regulatory strategy for ZYBRESTAT in ATC, including seeking additional financing for the FACT 2 study, with the goal of initiating this pivotal trial in 2012."

Commented Claus Moeller, Chief Executive Officer of Azanta: "Partnering with OXiGENE to distribute ZYBRESTAT to European and Canadian ATC patients under appropriate regulatory auspices reflects our strategy to build industry leadership by making innovative developmental therapies available to patients in international markets. We believe that ZYBRESTAT has generated an impressive body of safety and activity data, with a suggested survival benefit in ATC, and has significant therapeutic and commercial potential. We are pleased to make our distribution and regulatory expertise available to help advance this promising therapeutic option, and we look forward to a productive collaboration."

ABOUT ZYBRESTAT

OXiGENE believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

MICROMET INCORPORATED (NASDAQ: MITI)
"Up 32.13% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/MITI.php

Micromet is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Micromet is advancing a robust pipeline of novel therapeutics based on its proprietary BiTE® technology. Micromet's lead product candidate blinatumomab is currently the subject of a European trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and Sanofi.

MITI News:

January 26 - Amgen to Acquire Micromet

* Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies
* Micromet's Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types
* All-Cash Transaction Values Micromet at $1.16 Billion

Amgen (NASDAQ: AMGN) and Micromet, Inc. (NASDAQ: MITI) announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was unanimously approved by both the Amgen and Micromet Boards of Directors.

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

"The acquisition of Micromet is an opportunity to acquire an innovative oncology asset with global rights and a validated technology platform with broad potential clinical applications," said Kevin Sharer, chairman and CEO at Amgen. "Blinatumomab will serve as an important complement to our oncology pipeline and is representative of our corporate strategy, which is focused on developing and successfully commercializing therapeutics to treat patients with grievous illness."

Amgen will gain the following as a result of the acquisition:

1) Blinatumomab, a BiTE antibody that has demonstrated encouraging single-agent activity in both adult and pediatric patients with ALL as well as adult patients with NHL, and is currently under investigation in five trials:

2) Proprietary BiTE antibody technology which provides an innovative, validated platform for future clinical research

3) Potential milestone and royalty payments from existing licensees of BiTE and other technologies

4) Unencumbered rights to solitomab, a BiTE antibody in Phase 1 for patients with advanced solid tumors

5) Micromet's Munich site, which will operate as an Amgen R&D center of excellence

"We believe that this transaction represents an attractive opportunity for Micromet, its stockholders and cancer patients," said Christian Itin, Ph.D., Micromet's president and CEO. "Amgen's extensive resources and experience in the development and commercialization of biologics promise to speed blinatumomab's path to market, expand its development across a broader range of B-cell malignancies and maximize the full potential of our novel BiTE technology."

Terms of the Transaction

Under the terms of the merger agreement, a subsidiary of Amgen Inc. will commence a tender offer to acquire all of the outstanding shares of Micromet's common stock at a price of $11 per share in cash. Following the purchase of shares through the tender offer, Amgen will complete the transaction by acquiring all remaining shares not acquired in the offer through a merger at the same price as the tender offer. The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Micromet shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act and other customary conditions. The tender offer is not subject to a financing condition. The transaction is expected to close in the first quarter.

Amgen is advised by Moelis & Company LLC and Sullivan & Cromwell LLP. Goldman, Sachs & Co. and Cooley LLP are acting as financial and legal advisors, respectively, to Micromet.

Amgen will discuss the transaction as part of its fourth quarter earnings conference call today with the investment community at 2:00 p.m. Pacific Standard Time.  The previously scheduled conference call will primarily address Amgen's fourth quarter and full year financial results.  Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call, including the question and answer session, is expected to last approximately one hour.

The webcast of the conference call, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

ABOUT AMGEN

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

ABOUT BLINATUMOMAB

Blinatumomab is a Bispecific T cell Engager (BiTE antibody) designed to direct a patient's cytotoxic T cells to eliminate cancer cells that express CD19. CD19 is a protein expressed on the surface of B-lymphocytes including acute lymphoblastic leukemias and non-Hodgkin's lymphomas.  Data on blinatumomab demonstrating a high complete remission rate in adult patients with relapsed/refractory B-precursor ALL was recently reported at the American Society of Hematology (ASH) Annual Meeting, held in December 2011.

ABOUT BITE TECHNOLOGY

BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically, antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. BiTE antibodies have been shown to bind T cells to tumor cells, ultimately killing the tumor cells.

ENTREMED INCORPORATED (NASDAQ: ENMD)
"Up 26.61% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/ENMD.php

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.

ENMD News:

January 23 - EntreMed Secures $10 Million Strategic Financing

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P. ("IDG"), Emerging Technology Partners, LLC ("ETP"), and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.

The Company entered into purchase agreements with the investors, pursuant to which the Company has agreed to issue and sell to the investors convertible notes in the aggregate principal amount of $10 million.  The investors also will be issued warrants covering a number of shares of common stock equal to 20% of the principal amount of the notes, divided by $1.15.  The warrants are exercisable at $1.40 per share.  The closing of the transaction is anticipated to occur on or about January 27, 2012 upon the satisfaction of certain conditions.

At the closing, IDG and ETP have the right to designate in the aggregate two members of the Company's Board of Directors.  In addition, it is expected that the Company will select an interim Chief Executive Officer.

Subject to the approval of the Company's stockholders at the 2012 stockholder meeting, the notes will automatically and immediately convert into shares of common stock and the warrants will become exercisable.  The notes have a maturity date of August 31, 2012, bear an interest rate of 6% and will convert at a conversion price of $1.15 per share.  The conversion price reflects the 10-day average closing sale price ending on January 20, 2012.  The notes are not convertible, and the warrants are not exercisable, prior to receiving stockholder approval.  If stockholder approval is not obtained, the Company will be required to pay liquidated damages to the note purchasers equal to an aggregate of $1.2 million.

"We are very pleased to have the support from a group of knowledgeable investors and the validation of the potential of ENMD-2076. The proceeds from the notes will allow the Company to accelerate and expand its research and development activities, fund additional trials, initiatives and long term strategic plans," said Michael M. Tarnow, the Company's Executive Chairman.

After deducting transaction fees and expenses, the net proceeds to the Company will be approximately $9.3 million.  The convertible notes, the warrants and the common stock into which the notes and warrants are convertible have not been registered under the Securities Act of 1933, as amended (the "Act") and applicable state securities laws, but have been offered and sold in the United States pursuant to applicable exemptions from registration requirements under the Act and applicable state securities laws. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state.

ABOUT ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.

NX GLOBAL INCORPORATED (OTCBB: NEGS)
"Up 50.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/NEGS.php

NX Global, Inc. engages in renewable energy activities in the United States. It operates in three divisions: Renewable Energy Project Management, Renewable Energy Product Sales, and Green Internet Technologies. The Renewable Energy Project Management division provides project management and marketing services to solar/thermal, bio-fuels, and waste to energy project owners. Its projects include bio-fuel from algae and from pyrolisis of tires, pyrolisis of municipal solid waste to energy, and combination operations of solar/thermal and animal waste pyrolisis. The Renewable Energy Product Sales division markets products produced from the other divisions, such as algae oil for fuel and its biomass for nutraceutical and animal feed to recyclers and other businesses, as well as lighting and water systems for commercial structures. The Green Internet Technologies Service and Training division offers green social networking products and services, and training for new technology development and certification in the virtualization and cloud computing markets. The company was founded in 1995 and is based in Austin, Texas.

NEGS News:

October 27 - NX Global, Inc. Announces Corporate Action

NX Global, Inc. (OTCBB: NEGS) announced that a reverse split of its common stock 1:100 will be effective at the market open October 28, 2011 and trade under the symbol "NEGSD" for twenty business days before reverting to "NEGS."

The company also announced that a joint venture previously announced with the United Women's Football League was terminated by the company.

NX Global, Inc. is negotiating for joint ventures and acquisitions with "green" businesses and products. These agreements are expected to be completed in November.

ISC8 INCORPORATED (OTCBB: IRSN)
"Up 10.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/IRSN.php

ISC8, Inc. is actively engaged in the development and sale of intelligent Cybersecurity solutions for information technology (IT) for commercial and government environments worldwide. To provide multiple hardware, software and cloud-based product and service offerings that enable Enterprise Threat Management it leverages anti-tamper, 3D stacked chip assemblies, high-speed processors, and miniaturized sensors – all technologies it was instrumental in developing. The company's other division manufactures and sells thermal imaging systems for current U.S. Military force platforms. ISC8, Inc. was founded in 1974 and is headquartered in Costa Mesa, California.

IRSN News:

January 25 - ISC8 and Falcon Electronics Sign Distribution Agreement

Partnership Focuses on Anti-Tamper & 3D Stacking

ISC8, Inc. (OTCBB: IRSN) announced the company has signed an agreement with Falcon Electronics to distribute its line of 3D stacked chip and high-speed memory products and services. This new partnership provides a direct channel for ISC8 products into the large system builders and integrators that are looking for either secure components or systems in a package solution for their customers.

The ISC8 portfolio has grown further with the launch of its customizable stacking and packaging designed to meet the increased demand for high reliability and performance in very small form factors by providing small, highly integrated, systems-in-a-cube. This new partnership will provide an additional level of value to Falcon's customers.

Bill Joll, President and CEO of ISC8, commented: "We have ambitious plans for the 3D stacking market. Falcon is the natural choice of partner to help us drive forward given their expertise in selling and delivering superior customer service. Furthermore, their experience with Military and Aerospace customers selling and supporting complimentary technologies from leading vendors make them an ideal strategic partner."

ISC8's time-to-market oriented approach and flexibility are important to our customers," said Brian Diaz, President of Falcon Electronics. "The agreement holds great synergies. By combining ISC8's expertise in this market segment with Falcon's world-class support focus and logistics capabilities will facilitate rapid progression in existing and emerging sectors, and collectively we will grow our share."

ABOUT FALCON ELECTRONICS, INC.